| Challenges in vascular repair by endothelial progenitor cells in diabetic patients. | |
| | |
MedLine Citation:
|
PMID: 20678063 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Endothelial progenitor cells (EPCs) are a special type of stem cells, derived from bone marrow that can be mobilized to the peripheral circulation in response to many stimuli. EPCs play a crucial role in the vascular repair, as well as in neovascularization processes. Recent studies have shown that EPCs are impaired, both in number and function, in diabetic patients independently of other cardiovascular risk factors. Accelerated atherosclerosis is probably the most devastating among diabetes complications and endothelial dysfunction might be the beginning of the atherosclerosis. The impairment of EPCs seems to significantly contribute to atherogenesis and atherosclerotic disease progression in diabetes. Autologous EPCs therapy represents a novel treatment option for vascular complications requiring therapeutic revascularization and vascular repair. Diabetic patients represent a population that may benefit from cell-based therapy; however the dysfunction of their endogenous cells may limit the feasibility of this approach. In fact, EPCs isolated from these patients for autologous cell transplantation may retain their dysfunctional characteristics in vivo and as a consequence display a reduced capacity to improve therapeutic neovascularization. In the present review, we summarize the most relevant mechanisms of EPC dysfunction in diabetes. |
| | |
Authors:
|
Natália António; Rosa Fernandes; Carlos Fontes Ribeiro; Luís A Providência |
Related Documents
:
|
435423 - Development and classification of rubeosis iridis in diabetic eye disease. 9217873 - Endothelial dysfunction and pathogenesis of diabetic angiopathy. 15322863 - Insulin resistance, its consequences for the clinical course of the disease, and possib... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Cardiovascular & hematological disorders drug targets Volume: 10 ISSN: 1871-529X ISO Abbreviation: Cardiovasc Hematol Disord Drug Targets Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2011-01-20 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101269160 Medline TA: Cardiovasc Hematol Disord Drug Targets Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 161-6 Citation Subset: IM |
Affiliation:
|
Serviço de Cardiologia, Hospitais da Universidade de Coimbra, Avenida Bissaya Barreto, 3000-076 Coimbra, Portugal. natalia.antonio@gmail.com. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Stem cell-based therapies for heart regeneration: what did the bench teach us?
Next Document: Stem cell therapy in chronic ischemic heart dysfunction with and without viability.